Trials / Completed
CompletedNCT01521585
A Phase II Safety and Tolerability Study With SEN0014196
A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (actual)
- Sponsor
- Siena Biotech S.p.A. · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SEN0014196 | 50 mg oral once daily tablet |
| DRUG | SEN0014196 | 200 mg oral once daily tablet |
| DRUG | Placebo | oral once daily tablet |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-01-30
- Last updated
- 2015-11-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01521585. Inclusion in this directory is not an endorsement.